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INTRODUCTION
Myasthenia gravis (MG) is an autoimmune disorder affecting 
neuromuscular transmission.1,2 MG is the most common neu-
romuscular junction disorder, although estimates of its fre-
quency vary. A large number of population-based epidemio-
logical studies of MG have been performed worldwide since 
the 1950s. A meta-analysis of 55 epidemiological studies esti-
mated a prevalence of 77.7 per million people and an incidence 
of 5.3 per million person-years.3 However, the prevalence and 
incidence of MG varied markedly between the populations in-
vestigated. The prevalence ranged from 15 to 179 per million 
people, and the incidence ranged from 1.7 to 21.3 cases per 
million person-years.3 Therefore, in unstudied populations, 
the prevalence and incidence rates are very hard to extrapolate 
from previous studies. In Korea, no population-based epide-
miological studies were known to have been performed.
The Republic of Korea has a public medical insurance sys-
tem, National Health Insurance (NHI), which covers almost all 
of the Korean population.4 Under NHI, the Health Insurance 
Review and Assessment Service (HIRA) evaluates the medical 
fees, quality of care, and adequacy of medical services. To per-
form such evaluations on these public services, HIRA collects 
data for each patient, including diagnoses, treatments, proce-
dures, and prescription drugs. The HIRA database has been 
used for a number of epidemiological studies of medical disor-
ders, for example, multiple sclerosis, Huntington’s disease, and 
postherpetic neuralgia.5-7
The purpose of this study was to estimate the prevalence 
and incidence of MG in Korea by utilizing the HIRA database.
MATERIALS AND METHODS
Sources of data and data selection
Under the Korean NHI system, health care institutions (i.e., 
hospitals and clinics) ask the NHI Service to pay for their medi-
cal expenses. After HIRA reviews the NHI claims, the NHI Ser-
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vice reimburses the health care institutions for their medical 
expenses. HIRA data are obtained from the payment claims 
form that is generated from each inpatient or outpatient visit to 
a health care institution. HIRA provides detailed data includ-
ing patient demographics, diagnoses, procedures, and any 
prescription drugs taken. For research analyses, personal iden-
tifiers are replaced by surrogate identification numbers to pro-
tect personal information. Researchers can combine data from 
multiple claims into a single entry for each patient.
We filtered the HIRA data to determine the total MG popula-
tion. Among all payment claims between 2010 and 2014, we 
extracted only claims in which the main or secondary cause of 
the visit was MG (G70 or G70.0), as defined by the Internation-
al Classification of Diseases, 10th revision. To increase the di-
agnostic accuracy, we selected only exact cases by using the 
operational definition of MG. Only the data of individuals who 
visited a neurologist, pediatrician, or ophthalmologist were 
included in this study. An individual was defined as having 
MG if he or she visited a health care institution for MG at least 
twice during the study period. To estimate the annual inci-
dence, a new MG case was defined as an individual who met 
both of the following criteria: 1) payment claims had never 
been made before each year in the study period; and 2) the 
prescription drug code for pyridostigmine bromide or oral 
corticosteroids, such as prednisolone, was present. The num-
ber of new MG cases in 2010 could not be calculated due to 
the lack of data for the previous year. 
Estimation of prevalence and incidence
The population data for the Republic of Korea between 2010 
and 2014 were obtained from the Korean Statistical Informa-
tion Service (KOSIS; http://kosis.kr/). The total population 
ranged from 47.99 to 50.42 million during the study period. 
The population stratified by sex and 5-year age intervals was 
also provided by KOSIS (Fig. 1). The annual prevalence and in-
cidence were calculated by dividing the number of total MG 
and new MG cases by the total population of each year, respec-
tively. As the incidence and prevalence of MG varied among 
sex and age groups, averaged sex- and age-specific prevalence 
and incidence were calculated based on the numbers of total 
MG and new MG cases in each sex and 5-year age interval 
and the stratified population data. 
This study was approved by the Institutional Review Board 
(IRB) of Severance Hospital, Yonsei University Health System 
(IRB No.: 4-2015-0330). HIRA data access was approved and 
offered by HIRA.
Statistics
A chi-square test was performed to compare prevalence and 
incidence according to sex and age groups, and 95% confi-
dence intervals (CIs) that did not contain 1 and p<0.05 were 
considered statistically significant for all analyses. All statisti-
cal analyses were performed using SPSS version 20.0 software 
(SPSS Inc., Chicago, IL, USA).
RESULTS
The incidence and prevalence of MG are presented in Table 1.
A total of 10138 MG cases (male: 4133; female: 6005) were 
identified during the study period. Fig. 2 demonstrates the 
number of MG cases according to age in 2012. The number of 
Fig. 1. The population pyramid in 2010, South Korea.
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MG cases increased steadily from people aged 10–14 years to 
those aged 50–54 years. After peaking at 50–54 years of age, 
the number of cases decreased continuously as age increased. 
This pattern was similar in both males and females. The num-
ber of MG cases was approximately 1.5 times higher in females 
than in males. The ratio of females to males ranged from 1.1 to 
3.0 according to age.
The annual prevalence of MG increased steadily from 10.42 
cases per 100000 people in 2010 to 12.99 cases per 100000 peo-
ple in 2014. This rising tendency was observed in both males 
and females. The prevalence ratio of females to males was ap-
proximately 1.6. Fig. 3 shows the age-specific prevalence in 
2012. In females, the prevalence of MG tended to increase from 
people aged 10–14 years to those aged 50–54 years; then, the 
prevalence reached a plateau up to those aged 75–79 years. 
After the age of 80, the prevalence decreased sharply as age 
increased. In males, the prevalence tended to increase with age 
from 10–14 years to 65–69 years. After peaking at 65–69 years, 
the prevalence tended to decrease as age increased. The prev-
alence was higher in the older (≥50) age groups than in the 
younger (<50) age groups [prevalence: 9.26 vs. 19.24 per 
100000; relative risk (RR): 2.077; 95% CI: 1.976–2.183; p<0.001] 
(Table 2).
There were 1316 new MG cases (male: 564; female: 752) 
Fig. 2. The number of MG cases in 2012 (A: by age group, B: by sex and age group). MG, myasthenia gravis.
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Fig. 3. The prevalence in 2012 (A: by age group, B: by sex and age group). MG, myasthenia gravis.
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Table 1. Incidence and Prevalence of MG in Korea
Year
Total population Total cases F/M ratio  
of cases*
Prevalence rate  
per 100000
New cases
Incidence rate  
per 100000
T M F T M F T M F T M F T M F
2010 47990761 23840896 24149865 5001 1920 3081 1.6 (1.1–3.0) 10.42 8.05 12.76 
2011 49779440 24942339 24837101 5493 2134 3359 1.5 (1.2–2.8) 11.03 8.56 13.52 292 116 176 0.59 0.47 0.71 
2012 50004441 25039557 24964884 6201 2411 3790 1.6 (1.2–2.8) 12.40 9.63 15.18 390 174 216 0.78 0.69 0.87 
2013 50219669 25132612 25087057 6513 2557 3956 1.5 (1.2–2.4) 12.97 10.17 15.77 355 165 190 0.71 0.66 0.76 
2014 50423955 25219810 25204145 6551 2601 3950 1.5 (1.3–2.2) 12.99 10.31 15.67 279 109 170 0.55 0.43 0.67 
F, female; M, male; T, total; MG, myasthenia gravis.
*(bracket), range of F/M ratio according to age group.
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Prevalence and Incidence of MG in Korea
during the study period. The number of new MG cases accord-
ing to age is illustrated in Fig. 4. The number of new MG cases 
tended to increase with age from 5–9 years. The number of new 
MG cases peaked at 55–59 years. After the age of 60, the num-
ber of new MG cases decreased as age increased. Both males 
and females showed similar tendencies. In those aged 15–19 
years, however, a difference in new MG cases between males 
and females was noticeable.
The average incidence of MG between 2011 and 2014 was 0.69 
cases per 100000 person-years. The annual incidence ranged 
from 0.55 to 0.71 cases per 100000 person-years. Fig. 5 pres-
ents the age-specific incidence during the study period. The 
incidence tended to increase from 10–14 years to 55–59 years; 
then, the incidence reached a plateau up to 80–84 years. After 
the age of 85, a steep drop-off in the incidence was observed. 
The incidence was higher in the older (≥50) age groups than in 
the younger (<50) age groups (incidence: 0.47 vs. 1.18 per 
100000; RR: 2.490; 95% CI: 2.006–3.091; p<0.001) (Table 2). Al-
though the pattern of age-specific incidence was similar in 
males and females, the incidence in those aged 15–19 years 
was significantly higher in females than in males (0.51 vs. 0.16 
per 100000; RR: 3.115; 95% CI: 1.609–6.031; p<0.001) (Table 3). 
DISCUSSION
The present study is the first population-based epidemiologi-
cal study on MG in the Republic of Korea, which has a popu-
lation of about 50 million. In addition, this study used data 
representing the entire national population. The prevalence of 
MG was estimated as 10.42–12.99 per 100000 people, and the 
incidence was 0.69 cases per 100000 person-years. These re-
sults were consistent with those of previous studies in which 
the prevalence ranged from 1.5 to 17.9 per 100000 people and 
the incidence ranged from 0.17 to 2.13 cases per 100000 per-
son-years.3,8,9 
Table 2. Comparison of Prevalence and Average Incidence between Younger-Age and Older-Age MG Cases
Young age (<50) Old age (≥50) Relative risk (95% CI) p value
Prevalence (per 100000) 9.26 19.24 2.077 (1.976–2.183) <0.001
Incidence (per 100000) 0.47 1.18 2.490 (2.006–3.091) <0.001
CI, confidence interval; MG, myasthenia gravis.
Fig. 4. The new MG cases during the study period (A: by age group, B: by sex and age group). MG, myasthenia gravis.
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Fig. 5. Average incidence from 2011 to 2014 (A: by age group, B: by sex and age group). MG, myasthenia gravis.
1.60
1.40
1.20
1.00
0.80
0.60
0.40
0.20
0.00
Total
Av
er
ag
e 
in
cid
en
ce
 o
f M
G 
(2
01
1–
20
14
)
A
1.60
1.40
1.20
1.00
0.80
0.60
0.40
0.20
0.00A
ve
ra
ge
 in
cid
en
ce
 o
f M
G 
(2
01
1–
20
14
)
FemaleMaleB
423http://dx.doi.org/10.3349/ymj.2016.57.2.419
Hyung Seok Lee, et al.
Several issues of the present study must be considered. 
First, we used operational definitions of MG cases and new 
MG cases for diagnostic accuracy. In this study, case identifi-
cation was based on diagnostic coding by medical doctors. 
Neurologists, pediatricians, and ophthalmologists are consid-
ered to be MG specialists in Korea. In addition, most patients 
have easy access to medical specialists throughout the coun-
try. Therefore, almost all suspected patients of MG visit at least 
one of these three kinds of medical specialists in Korea. This is 
one reason why MG cases could not be determined according 
to medical specialty. Considering that MG is a chronic dis-
ease, individuals with only one visit for MG were also exclud-
ed. To define new MG cases, we used prescription drug codes 
for pyridostigmine bromide or oral corticosteroids. HIRA pro-
vided only 5 years of data. If the drug codes were not applied, 
new MG cases would have included certain amounts of well-
controlled MG patients without medication who made visits 
to a doctor only at long intervals. For example, MG patients 
classified as minimal manifestation–0 (Myasthenia Gravis 
Foundation of America post-intervention status) who visited 
a doctor in 2009 and 2011 would have been regarded as new 
MG cases in 2011 in this study. Second, the age of age-specific 
incidence represents that of the first visit for MG, not the age 
of symptom onset in this study. The age of symptom onset 
was not available in the HIRA database. According to a previ-
ous study, the median periods from onset of MG to the first 
visit to a doctor and from onset of MG to diagnosis were 1.0 
and 6.1 months, respectively.10 Although the age of the first 
visit for MG was greater than that of MG onset, the age differ-
ence may have had only a minor influence on age-specific in-
cidence based on 5-year age intervals.
The most noticeable observation of this study was the high 
prevalence and incidence of MG in the older age group. A Tai-
wanese population-based epidemiological study also showed 
the predominance of elderly MG patients.11 The incidence of 
elderly-onset MG has been increasing across the world.12 In 
Japan, the incidence of MG patients with an onset age of 65 
years or more has doubled in the past two decades.13 A number 
of epidemiological studies from the United States and Europe 
also revealed a similar tendency. Distinct immunological char-
acteristics of elderly patients, the occurrence of thymoma, and 
environmental factors have been suggested as causes of the 
increasing incidence of elderly MG patients. However, the rea-
son for this growing incidence remains unclear. 
In the most elderly age group of this study, the incidence of 
MG dropped off very steeply. This pattern was also observed 
in a previous study, which demonstrated the high prevalence 
of unrecognized positive anti-acetylcholine receptor antibod-
ies in the most elderly age group.14 In addition, ocular myasthe-
nia is more common in older people than in younger people.15 
The diagnosis of ocular myasthenia can be difficult. These find-
ings suggest that MG may be underdiagnosed in a substantial 
number of very elderly people. The prevalence of this study 
also decreased after the age of 70. Although the underdiagno-
sis of MG may be one of the reasons, this finding remains dif-
ficult to explain. Another possible explanation is the low ac-
cessibility of health care institutions for very elderly patients 
with MG. In this study, only MG patients who visited health 
Table 3. Average Age- and Sex-Specific Incidence of MG, 2010–2014
Age group (yr)
Cases Average incidence per 100000
Relative risk (95% CI)
F/M incidence rate  
p valueT M F T M F
0–4 19 9 10 0.21 0.20 0.23 1.179 (0.479–2.900) 0.720 
5–9 12 3 9 0.13 0.06 0.20 3.240 (0.877–11.966) 0.062 
10–14 20 11 9 0.16 0.17 0.15 0.892 (0.370–2.152) 0.799 
15–19 45 12 33 0.33 0.16 0.51 3.115 (1.609–6.031) <0.001
20–24 53 22 31 0.43 0.34 0.54 1.602 (0.927–2.766) 0.088 
25–29 69 30 39 0.49 0.42 0.56 1.350 (0.839–2.173) 0.215 
30–34 99 44 55 0.67 0.59 0.75 1.276 (0.858–1.896) 0.228 
35–39 93 44 49 0.57 0.53 0.60 1.125 (0.749–1.691) 0.570 
40–44 114 50 64 0.69 0.60 0.78 1.287 (0.889–1.863) 0.180 
45–49 121 51 70 0.74 0.62 0.86 1.383 (0.964–1.984) 0.077 
50–54 148 63 85 0.97 0.83 1.11 1.334 (0.963–1.847) 0.082 
55–59 150 68 82 1.36 1.25 1.46 1.167 (0.846–1.610) 0.346 
60–64 101 50 51 1.16 1.18 1.13 0.958 (0.649–1.415) 0.830 
65–69 100 45 55 1.38 1.35 1.40 1.040 (0.702–1.543) 0.844 
70–74 75 30 45 1.20 1.11 1.26 1.130 (0.712–1.794) 0.604 
75–79 60 20 40 1.38 1.22 1.48 1.219 (0.713–2.086) 0.468 
80–84 30 10 20 1.26 1.34 1.22 0.908 (0.425–1.941) 0.804 
≥85 7 2 5 0.48 0.53 0.46 0.871 (0.169–4.490) 0.869 
F, female; M, male; T, total; CI, confidence interval; MG, myasthenia gravis.
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care institutions were identified as MG cases. If they did not 
visit a doctor, it was not possible for them to be included as 
subjects in this study. 
Korea is one of the fastest aging countries in the world. It is 
anticipated that the proportion of elderly people will be more 
than 20% by 2026.16 Considering the high prevalence and inci-
dence of MG in the older age group, the number of elderly pa-
tients with MG will increase very rapidly in Korea. As elderly 
patients are prone to additional diseases, physicians will be 
faced more frequently with complicated MG patients, for ex-
ample, MG patients with diabetes mellitus or osteoporosis. 
The management of MG patients will be more complex, and 
the medical costs associated with MG will likely increase in 
the coming years. Further studies on the comorbidities and 
medical costs of MG are necessary to prepare for the increas-
ing number of elderly patients with MG.
Although the characteristic bimodal pattern of age- and 
sex-specific incidence was not demonstrated in this study, the 
incidence at 15–19 years of age was significantly higher in fe-
males than in males. This observation may reflect female pre-
dominance, particularly in early-onset MG. As in other auto-
immune diseases, female predominance has been thought to 
represent certain effects of sex hormones.17 A previous animal 
model study showed that estrogen enhances susceptibility to 
experimental autoimmune MG through the action on acetyl-
choline receptor-specific T and B cell responses.18 Fluctuations 
in disease activity during pregnancy or menstrual periods also 
suggest the possible effects of sex hormones on MG.19,20
There were several limitations in this study. First, we identi-
fied MG cases based on diagnostic coding. Clinical informa-
tion including medical history, anti-acetylcholine receptor 
antibody titer, and results of electrodiagnostic and pharmaco-
logical tests were not available in the HIRA database. Accord-
ingly, there was concern regarding the diagnostic accuracy. 
Second, we used operational definitions for MG cases and 
new MG cases to increase the diagnostic accuracy. Therefore, 
we could have missed actual cases of MG that did not meet 
the inclusion criteria. Diagnosis of MG depends mainly on the 
physician’s decision. In a substantial number of patients with 
MG, particularly ocular type, laboratory tests for MG diagno-
sis did not support the clinical diagnosis. For this reason, the 
issue of diagnostic accuracy is present in all epidemiological 
studies of MG. Third, the age data of this study was based on 
the time at which patients visited a doctor for MG. Conse-
quently, the age-specific incidence results must be interpreted 
with caution. In this study, the bimodal pattern of the age- 
and sex-specific distributions, which was an early peak in the 
twenties for females and a late peak in those over 50 for males, 
was not obvious, although the incidence for those aged 15–19 
years was significantly higher in females than in males. In ad-
dition, the high frequency of childhood-onset MG, which has 
been reported in Asian countries, was not demonstrated. The 
issues related to the age data may partially account for these 
discrepancies between the previous studies and the present 
study. Further studies combining the HIRA database with a 
national registry or survey for MG are necessary to improve 
the accuracy of diagnosis and clinical information, including 
the age of symptom onset. 
In conclusion, this first Korean epidemiological study on 
MG estimated the prevalence as 10.42–12.99 per 100000 peo-
ple and the incidence as 0.69 cases per 100000 person-years in 
the early 2010s. The prevalence and incidence were higher in 
the older age group. It is recommended to develop a strategy 
for the growing number of elderly patients with MG.
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